Stockscreener 앱 받기
1.78%
시간 외 거래:
전일 마감가:
$347.84
열려 있는:
$347.08
하루 거래량:
3.38M
Relative Volume:
1.27
시가총액:
$184.40B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
23.76
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
+1.16%
1개월 성능:
+4.70%
6개월 성능:
+4.80%
1년 성능:
+17.79%
1일 변동 폭
$338.90
$349.40
1주일 범위
$338.90
$358.46
52주 변동 폭
$267.83
$391.29
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, NVS, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
341.66 | 189.18B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,112.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.20 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.23 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.88 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.44 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Amgen Hires Lobbying Counsel on Drug Pricing - Legis1
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
New phase 3 data put Amgen’s Repatha back in the lipid spotlight - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Jury patent verdict and valuation debate put shares in focus - AD HOC NEWS
Amgen Owes $20 Million in Antibody-Production Tech Patent Trial - Bloomberg Law News
Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355 - GuruFocus
The litigation lasted five years, and Amgen was found to have willfully infringed. Harbour BioMed stated, 'The favorable ruling is expected to enhance our BD negotiation leverage.' | Quick Read Announcement - 富途牛牛
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Amgen (AMGN) Stock After Horizon Deal And Strong Multi‑Year Gains Is Price Still Reasonable - simplywall.st
Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial - Law360
Amgen owes $20.2 million in antibody patent lawsuit, US jury says - marketscreener.com
Amgen Defends Rare Disease Drug in FDA Crosshairs - MedCity News
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says - TradingView
Amgen Defends Tavneos Amid FDA Withdrawal Proposal - GuruFocus
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial - TipRanks
Cash from investing activities of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug - Investing.com
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug By Investing.com - Investing.com Canada
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight - GuruFocus
(AMGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $427 - Moomoo
Amgen Inc. $AMGN Position Reduced by Vaughan David Investments LLC IL - MarketBeat
Swiss National Bank Has $482.87 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - The Motley Fool
ICICI Prudential Asset Management Co Ltd Has $8.87 Million Stake in Amgen Inc. $AMGN - MarketBeat
9,812 Shares in Amgen Inc. $AMGN Bought by Meiji Yasuda America Inc - MarketBeat
Nuveen LLC Sells 86,287 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock (US0311621009): Shares Jump On EU Cancer Drug Approval And New Trial Data - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Dow component under pressure after recent pullback - AD HOC NEWS
Aviva PLC Purchases 23,465 Shares of Amgen Inc. $AMGN - MarketBeat
A Look at Amgen Inc (AMGN) After 4.8% Gain -- GF Value $353.35 v - GuruFocus
Amgen (AMGN) Faces FDA Scrutiny Over Tavneos Amid Safety Concerns - GuruFocus
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
0.23%
자본화:
|
볼륨(24시간):